Teyi Pharmaceutical Group Co.,Ltd (SHE:002728)
China · Delayed Price · Currency is CNY 11.08
-0.17 (-1.51%)
Apr 9, 2026, 3:04 PM CST
SHE:002728 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Net Income | 81.67 | 20.5 | 253.18 | 178.2 | 126.92 |
Depreciation & Amortization | 69.82 | 64.37 | 60.1 | 52.52 | 51.31 |
Other Amortization | 0.01 | 0.05 | 0.07 | 0.07 | 0.07 |
Loss (Gain) From Sale of Assets | 0.07 | -0 | -0.12 | -0.04 | -0.1 |
Asset Writedown & Restructuring Costs | 0.82 | 11.79 | 13.44 | 0.12 | 23.43 |
Loss (Gain) From Sale of Investments | -0.8 | -3.74 | -0.36 | -0.34 | -6.31 |
Provision & Write-off of Bad Debts | -1.27 | -0.04 | 0.07 | 0.6 | 0.1 |
Other Operating Activities | 4.73 | 5.95 | 16.32 | 30 | 31.27 |
Change in Accounts Receivable | 45.81 | -42.92 | -8.02 | -34.02 | 13.98 |
Change in Inventory | 25.09 | 6.7 | -63.6 | -12.75 | 5.39 |
Change in Accounts Payable | 25.89 | -85.03 | -72.84 | 157.24 | 13.17 |
Change in Other Net Operating Assets | 0.17 | 0.72 | -0.81 | -1.76 | -1.1 |
Operating Cash Flow | 244.09 | -22.55 | 198.56 | 371.66 | 256.81 |
Operating Cash Flow Growth | - | - | -46.58% | 44.72% | 51.97% |
Capital Expenditures | -79.55 | -113.56 | -86.05 | -90.26 | -109.58 |
Sale of Property, Plant & Equipment | 0.2 | 0.02 | 0.16 | 0.09 | 0.52 |
Investment in Securities | 600 | 1,784 | - | -13.5 | 250 |
Other Investing Activities | -809.2 | -1,780 | 0.36 | 0.34 | 6.31 |
Investing Cash Flow | -288.55 | -109.8 | -85.53 | -103.33 | 147.25 |
Short-Term Debt Issued | 618.95 | 1,014 | 626.63 | 763.45 | 432.86 |
Total Debt Issued | 618.95 | 1,014 | 626.63 | 763.45 | 432.86 |
Short-Term Debt Repaid | -889 | -809 | -965.88 | -517 | -836.12 |
Total Debt Repaid | -889 | -809 | -965.88 | -517 | -836.12 |
Net Debt Issued (Repaid) | -270.05 | 204.78 | -339.26 | 246.45 | -403.26 |
Issuance of Common Stock | 15.44 | 13.88 | 282.83 | - | 184.91 |
Repurchase of Common Stock | -7.34 | -93.86 | - | - | - |
Common Dividends Paid | -24.91 | -182.31 | -149.02 | -147.62 | -138.38 |
Other Financing Activities | 154 | -54 | 100 | -200 | - |
Financing Cash Flow | -132.86 | -111.51 | -105.44 | -101.17 | -356.73 |
Net Cash Flow | -177.33 | -243.85 | 7.59 | 167.16 | 47.33 |
Free Cash Flow | 164.54 | -136.11 | 112.51 | 281.39 | 147.24 |
Free Cash Flow Growth | - | - | -60.02% | 91.11% | 85.05% |
Free Cash Flow Margin | 17.80% | -19.79% | 10.54% | 31.74% | 19.42% |
Free Cash Flow Per Share | 0.32 | -0.27 | 0.24 | 0.64 | 0.37 |
Cash Income Tax Paid | 91.28 | 62.57 | 101.92 | 67.5 | 67.94 |
Levered Free Cash Flow | 121.09 | -148.47 | -14.32 | 175.85 | 60.27 |
Unlevered Free Cash Flow | 123.74 | -145.15 | -4.09 | 194.06 | 78.72 |
Change in Working Capital | 89.04 | -121.42 | -144.14 | 110.52 | 30.12 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.